ECKERT & ZIEGLER BG 
By Seneffe - Belgium, May 6, 2014, Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB) has announced today its Interim Statement for the first quarter 2014. The report including a selection of consolidated key figures for the 3 months ending March 31, 2014 can be downloaded at:
www.bebig.eu > Investor Relations > Financial Reports:
http://www.bebig.eu/home/investor-relations/financial-reports.html
At EUR 6.5 million, sales in the first quarter of 2014 were considerably higher compared to EUR 5.5 million in the prior year. The increase in sales is exclusively a result of the recently acquired business in the US.
Eckert & Ziegler BEBIG
...Contributing to saving lives!
Eckert & Ziegler BEBIG, incorporated in 1996, is a European-based company active in the medical device segment of the health care industry.
Eckert & Ziegler BEBIG's core business is the treatment of cancer using brachytherapy, a special form of radiation therapy.
Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company headquarters are in Belgium, with a production facility in both Germany and the USA and subsidiaries throughout Europe as well as in India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing of its product line.
The company's products and equipment are intended for use by oncologists, radiologists, urologists, and medical physicists. Eckert & Ziegler BEBIG employs more than 200 people. The company has been listed on the NYSE Euronext Brussels stock exchange since April 1997 (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB).
Contact:
Eckert & Ziegler
BEBIG s.a.
Investor Relations
Tel.: +32 (0) 64 520 808
E-mail: ir@bebig.eu:
mailto:ir@bebig.eu
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Eckert & Ziegler BEBIG via Globenewswire
